Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
IOVA
Iovance Biotherapeutics
$1.75
Chart
$3.08 (-43.18%)
$3.75 (-53.33%)
$6.19 (-71.73%)
$8.16 (-78.55%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
IOVA
Iovance Biotherapeutics
Current Price
$1.75
Login to view Iovance Biotherapeutics (IOVA) recommendation from the last 90 days from financial news and social media.
Chart
$3.08 (-43.18%)
$3.75 (-53.33%)
$6.19 (-71.73%)
$8.16 (-78.55%)
IOVA Latest Headlines
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi &. Faruqi LLP. Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100000 in Iovance between August 8 2024 and May 8 2025 and...
Today
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi &. Faruqi LLP. Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100000 in Iovance between August 8 2024 and May 8 2025 and...
Today
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi &. Faruqi LLP. Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100000 in Iovance between August 8 2024 and May 8 2025 and...
Today
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi &. Faruqi LLP. Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100000 in Iovance between August 8 2024 and May 8 2025 and...
Today
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting. One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%
Thu May 22, 2025
Deadline Approaching: Iovance Biotherapeutics Inc. (IOVA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith. Law Offices of Howard G. Smith reminds investors of the upcoming July 14 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Iovance Biotherapeutics Inc. (Iovance or the Company) (NASDAQ: ) securities between May 9 2024 and May 8 2025 inclusive (the Class Period).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IOVANCE B
Tue May 20, 2025
Deadline Approaching: Iovance Biotherapeutics Inc. (IOVA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith. Law Offices of Howard G. Smith reminds investors of the upcoming July 14 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Iovance Biotherapeutics Inc. (Iovance or the Company) (NASDAQ: ) securities between May 9 2024 and May 8 2025 inclusive (the Class Period).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IOVANCE B
Tue May 20, 2025
Why Iovance Biotherapeutics Tumbled by Nearly 6% Today. Iovance Biotherapeutics (NASDAQ: IOVA) didnt quite end the stock trading week on a high note. The companys shares were dinged by almost 6% that day due largely to an analysts recommendation downgrade. This occurred on a generally positive day for equities as the S&.P 500
Fri May 16, 2025
Why Iovance Biotherapeutics Tumbled by Nearly 6% Today. Iovance Biotherapeutics (NASDAQ: IOVA) didnt quite end the stock trading week on a high note. The companys shares were dinged by almost 6% that day due largely to an analysts recommendation downgrade. This occurred on a generally positive day for equities as the S&.P 500
Fri May 16, 2025
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4). SAN CARLOS Calif. May 16 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics Inc. (NASDAQ: IOVA) (Iovance or the Company) a biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer today announced that on May 15 2025 (the Date of Grant) the Company approved the grant of inducement stock options covering an aggreg
Fri May 16, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
IOVA Stock trends
IOVA Stock performance
IOVA Stock analysis
IOVA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
